Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.
Michael Morse, MD, FACP, MHS, professor of medicine at Duke University School of Medicine and medical oncologist at Duke Cancer Center, discusses the etiologies of hepatocellular carcinoma (HCC) and how clinicians can tailor treatment for patients with varied levels of liver function.
Real-world evidence (RWE) provides critical knowledge for providers constructing a treatment regimen for patients diagnosed with hepatocellular carcinoma.